An Efficacy and Feasibility Analysis of Chinese Patent Medicine Combined With Letrozole in the Treatment of Women With Ovulation Disorders: A Network Meta-Analysis

Jing-Yan Zhu, Jian Liu, Xiao-Jing Cao and Xiao-Yun Wang

1Department of Gynecology, The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China, 2Department of Gynecology, Guangdong Hospital of Chinese Medicine, Guangzhou, China

Objective: To compare the efficacy of various listed Chinese patent medicines combined with letrozole in the treatment of ovulation disorders using network meta-analysis (NMA).

Methods: We conducted a systematic literature search in PubMed, Cochrane Central Register of Controlled Trials, Embase, Chinese Biomedical Literature, China National Knowledge Infrastructure, Wanfang, and VIP Information databases up to June 2020. Randomized controlled trials reporting Chinese patent medicine combined with letrozole for ovulation disorders were included. The Stata 13 and WinBUGS1.43 software were used for data analysis.

Results: A total of 24 randomized controlled trials were included, involving 2,318 patients. The results showed that when compared with patients using only letrozole, the ovulation rate was higher in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, Fufang Xuanju capsules, or Dingkun Dan; and Fufan Xuanju capsules showed the greatest improvement; the pregnancy rate was higher in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, or Dingkun Dan; and the endometrial thickness on the day of follicular maturity was greater in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, or Dingkun Dan. In terms of the sequencing of NMA results, Fufang Xuanju capsules combined with letrozole gave the best results in improving the ovulation rate and increasing the endometrial thickness, while Dingkun Dan combined with letrozole achieved the best results for improving the pregnancy rate.

Conclusion: Letrozole combined with Chinese patent medicine is more effective than letrozole alone in the treatment of ovulation disorders. Fufang Xuanju capsules is good at improving the ovulation rate and increasing the endometrial thickness. Dingkun Dan is good at improving the pregnancy rate. The appropriate choice of treatment should be made according to the actual clinical situation. This study is registered with the International Prospective Register of Systematic Reviews (CRD42020200603).

Keywords: Chinese patent medicine, letrozole, ovulation disorder, network meta-analysis, guiding clinical practice
INTRODUCTION

Ovulation disorders are a common cause of infertility or difficulty in achieving pregnancy in women of childbearing age. In infertile women, approximately 25–30% of patients have ovulatory dysfunction. (Xie et al., ) The induction of ovulation is the main treatment protocol for women with ovulation disorders who require fertility treatment. Letrozole is an aromatase inhibitor that can inhibit the transformation of androgen to estrogen and reduce the estrogen level. The negative feedback acts on the pituitary gland to encourage the secretion of gonadotropin and stimulate the development of the follicles. Letrozole is currently a commonly used clinical drug and has started to replace clomiphene as a first-line medicine. (Vitek and Hoeger, 2019) In gynecology or reproductive specialty departments of many Chinese and Western medicine hospitals in China, doctors will combine letrozole with gynecological Chinese patent medicine to promote the ovulation effect.

Many clinical studies have proven that a combination of Chinese patent medicine and letrozole in the treatment of ovulation disorders is more effective than using letrozole alone, and the combination of these drugs can increase the ovulation and pregnancy rates of patients and improve endometrial receptivity. Some of these studies have included meta-analyses of the combined treatment of some Chinese patent medicines and letrozole. However, there are currently few studies that have compared the efficacy of different Chinese patent medicines, making it difficult to evaluate the efficacy of various Chinese patent medicines when combined with letrozole in the treatment of ovulation disorders. Network meta-analysis (NMA) can summarize the existing evidence through direct comparisons, provide useful information through indirect comparisons, and rank the effects of various interventions to provide insights into the advantages and disadvantages of these interventions.

Therefore, this study uses the NMA method to systematically evaluate the efficacy of various Chinese patent medicines when combined with letrozole in the treatment of ovulatory disorders to provide evidence for clinical treatment.

METHODS

Protocol and Registration

This research followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for the Network Meta-Analysis checklist. (Hutton et al., 2015) The protocol was registered on the International Prospective Register of Systematic Reviews (registration number CRD42020200603).

Inclusion and Exclusion Criteria

We used the following inclusion criteria:

1) Participants: patients with ovulatory disorders (e.g., ovulatory infertility and polycystic ovary syndrome) requiring fertility treatment

2) Intervention: any kind of Chinese patent medicine combined with letrozole

3) Comparison: letrozole alone

4) Outcomes: change in ovulation rate, pregnancy rate, and endometrial thickness after the treatment

5) Study design: randomized clinical trial (RCT)

6) Language: English or Chinese studies

We excluded studies based on the following criteria:

1) studies not including the required outcomes

2) repeated publications

3) self-control studies and non-RCTs

4) preclinical studies, systematic reviews, case reports, and meta-analyses

5) protocols, unpublished studies, or duplicate studies

6) studies based on a research design with obvious defects or suspected fraud

Information Sources and Search Strategy

The Chinese Biomedical Literature, China National Knowledge Infrastructure, Wanfang, Weipu, PubMed, Embase, and Cochrane Central Register of Controlled Trials databases were searched to find RCTs on the use of Chinese patent medicine combined with letrozole in the treatment of ovulatory disorders.

Search words included Chinese medicine, patent medicine, herbal medicine, letrozole, Kuntai, Dingkun Dan, Fuke Zaizao, Bailing, Xiaoayao, Fuve Yangying, Fufang Xuanju, etc. The publication dates included were from the creation of each database to June 2020 (see Supplementary Table S1 for an example of the results retrieved from the PubMed database).

Literature Screening and Data Extraction

Literature screening and data extraction were carried out independently by two researchers. First, the literature titles were imported into NoteExpress, and duplicates were identified. Second, according to the inclusion criteria, two researchers read the literature titles and abstracts and excluded those that did not obviously meet the inclusion criteria. Finally, the full text of the literature was obtained and read to further exclude those that did not meet the inclusion criteria or met any of the exclusion criteria.

In the literature that was finally included, the data were extracted from the studies using a premade data extraction table that included the study code, patient information, baseline and comparable data, intervention and control measures, treatment course, and outcome indicators.

Quality Evaluation

Two researchers independently used the Cochrane risk of bias tool, as described in the Cochrane Handbook for Systematic Reviews of Interventions, to assess the quality of the RCT. Bias risks for each study were assessed based on six factors: random sequence generation, allocation concealment, blinding (performance and detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias, and they were ranked as high, low, or unclear risk. If there...
were differences of opinion, they were solved through discussion or with the assistance of a third party.

**Statistical Analysis**

**Direct Pairwise Meta-Analysis**

The ovulation and pregnancy rates are dichotomous variables, and the odds ratio (OR) was used to indicate the size of the effect. The endometrial thickness on the day of follicular maturity is a continuous variable, and the mean difference (MD) was used to indicate the quantity of the effect, and the 95% confidence interval (95% CI) of the OR and the MD were calculated. The RevMan 5.3 software was used for bias evaluation and direct pairwise meta-analysis. (Higgins et al., 2003)

Heterogeneity was quantitatively determined using I², with I² < 50% and p > 0.1 indicating no statistical heterogeneity. A fixed-effect model was used for meta-analysis. If statistical heterogeneity was found between the studies, subgroup and other methods were used to find the source of the heterogeneity, and if it could not be found, the random-effect model was used for meta-analysis. (Ades et al., 2006) A level of α = 0.05 was considered to be statistically significant.

**Network Meta-Analysis**

The Stata 13.0 software was used to create the evidence diagram for the NMA.

We conducted an NMA to estimate the effect for each class and for each individual intervention using the Markov chain Monte Carlo methods in WinBUGS (version 1.43, MRC Biostatistics Unit, Cambridge, United Kingdom). (Lu and Ades, 2004) Two chains with different initial values were run simultaneously to assess convergence using Brooks–Gelman–Rubin diagnostic plots. We used Markov chains for 50,000 simultaneous iterations after the first 5,000 iterations were discarded because they may have had an influence on the arbitrary values. The iteration history diagram was drawn to evaluate the degree of convergence of the model. The deviance information criterion (DIC) between the fixed-effect model and the random-effect model was used to judge the degree of fit of the model. (Dias et al., 2013) A difference in the DIC of <5 indicated a consistent fit between the two models, and therefore, both models could be adopted. If the difference was >5, the model with the smaller DIC was adopted. When there was a closed loop, the consistency between the direct and indirect comparison was determined by the inconsistency factor (IF) value. When the starting point of the 95% CI of the IF value was zero, the direct and indirect evidence were considered to be consistent. Finally, evidence of the small-sample effect in the network was identified by drawing a comparison-correction funnel plot.

**RESULTS**

**Literature Retrieval Process and Results**

A total of 200 related articles were obtained through the initial examination. After screening layer by layer, 24 RCTs (Li et al., 2015; Jian and Bai, 2016; Yang and Huang, 2016; Yang and Zhou, 2016; Chen, 2017; Liu, 2017; Hao and Xia, 2018; Ma, 2018; Wang et al., 2018; Yu et al., 2018; Zhang, 2018; Zhang et al., 2018; Zhong et al., 2018; Chen, 2019; Liu, 2019; Wang, 2019; Yang et al., 2019; Zhong et al., 2019; Chu et al., 2020; Fan and Xue, 2020; Li, 2020; Liang et al., 2020; Liu, 2020; Wei et al., 2020) were finally included, all of which were Chinese literature and involved a total of 2,318 cases. The literature screening process and results are shown in **Figure 1**.

**Basic Features of the Included Studies**

The results of this study were patients with ovulation disorders, all of whom were from studies that involved double-arm clinical trials, and a total of six kinds of Chinese patent medicine preparations were finally included from 15 studies of Kuntai capsules, two studies of Fuke Zaizao capsules, two studies of Fufang Xuanju capsules, 1 study of Fuke Yangying capsules, 1 study of Bailing capsules, and three studies of Dingkun Dan. Of these studies, 12 reported the ovulation rate (1,045 cases), 15 reported the pregnancy rate (1,442 cases), and 21 reported the endometrial thickness on the day of follicular maturity (2,070 cases) after treatment. The basic features of the included studies are shown in **Table 1**, and the assessment results of the risk of bias tests are shown in **Figure 2**.

**Pairwise Meta-Analysis**

The results of the pairwise meta-analysis showed that when compared with patients using only letrozole, the ovulation rate was higher in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, Fufang Xuanju capsules, or Dingkun Dan (α < 0.05), but there was no significant difference in patients using Fuke Yangying capsules combined with letrozole (α > 0.05); the pregnancy rate was higher in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, or Dingkun Dan (α < 0.05), but there was no significant difference in patients using Fuke Yangying capsules combined with letrozole (α > 0.05); and the endometrial thickness on the day of follicular maturity was greater in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, Fufang Xuanju capsules, Bailing capsules, or Dingkun Dan (α < 0.05). The results of the pairwise meta-analysis are shown in **Table 2**.

**Network Meta-Analysis**

**Evidence Network**

Three outcome indicators were considered, i.e., ovulation rate, pregnancy rate, and endometrial thickness on the day of follicular maturity. Star structure charts were created with letrozole as the center of the star structure. There were six intervention nodes in the ovulation rate star structure chart, five in the pregnancy rate star structure chart, and six in the endometrial thickness on the day of follicular maturity star structure chart. No closed loop was formed in any of the above evidence networks (see **Figure 3**).

**Model Selection**

When the results of the random-effect model are similar to those of the fixed-effect model, the data can be considered to be stable. The DICs of the ovulation rate and pregnancy rate were smaller in the fixed-effect model, and the DIC for endometrial thickness on
the day of follicular maturity was smaller in the random-effect model (see Table 3). Therefore, the fixed-effect model of the dichotomous variables (ovulation and pregnancy rates) and the random-effect model of the continuous variable (endometrial thickness on the day of follicular maturity) were used for data analysis in this study.

**Heterogeneity Test**

None of the three outcome indicators in this study exhibited a closed loop, so a consistency test was not necessary.

**Evaluation of the Small Sample Effect**

The comparison-correction funnel plot of the ovulation and pregnancy rates showed that all the studies were distributed symmetrically around the \( X = 0 \) line, and none of the studies fell outside of the funnel plot, indicating that there was no evidence of a small sample effect in the research network. However, in the comparison-correction funnel plot of the endometrial thickness on the day of follicular maturity, not all studies were symmetrically distributed around the \( X = 0 \) line, and nine studies were located outside the funnel plot, which provides evidence for the small sample effect in the research network (see Figure 4).

**Results of the Network Meta-Analysis of the Three Outcome Indicators**

**Ovulation Rate**

A total of 12 studies (Ji et al., 2015; Jian and Bai, 2016; Liu, 2017; Ma, 2018; Yu et al., 2018; Liu, 2019; Yang et al., 2019; Zhong et al., 2019; Chu et al., 2020; Li, 2020; Liang et al., 2020; Wei et al., 2020) reported the ovulation rate after treatment, which was higher in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, Fufang Xuanju capsules, or Dingkun Dan than in those using only letrozole and was significantly higher in patients using Fufang Xuanju capsules combined with letrozole than in patients using the other combinations, but there was no statistically significant difference between the other treatment results (see Table 4).

**Pregnancy Rate**

A total of 15 studies (Ji et al., 2015; Jian and Bai, 2016; Yang and Zhou, 2016; Liu, 2017; Ma, 2018; Wang et al., 2018; Yu et al., 2018; Zhang, 2018; Liu, 2019; Yang et al., 2019; Zhong et al., 2019; Chu et al., 2020; Li, 2020; Liu, 2020; Wei et al., 2020) reported the pregnancy rate after treatment, which was higher in patients using letrozole combined with Kuntai capsules, Fuke Zaizao capsules, or Dingkun Dan than in those using only
### TABLE 1 | Basic features of the included studies.

| No. | Literature code | Number of included cases | Age (year, \( \pm s \)) | Course of disease (months, \( \pm s \)) | Base-line comparability | Treatment measures and dosage | Control measures and doses | Course | Outcome |
|-----|----------------|--------------------------|--------------------------|--------------------------------------|--------------------------|-------------------------------|-----------------------------|--------|---------|
| 1   | Yang and Huang (2016) | 35 | 38.4 ± 2.3 | 26.5 ± 2.1 | 25 ± 1.1 | 24 ± 1.1 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×7D, Menstruation D5 begins | 50 days | ① |
| 2   | Yang and Zhou (2016) | 82 | 26.44 ± 3.67 | 26.53 ± 3.77 | not mentioned | not mentioned | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D3 begins | 4 weeks | ②③ |
| 3   | Chen (2017) | 40 | not mentioned | not mentioned | not mentioned | not mentioned | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×7D, Menstruation D5 begins | 50 days | ① |
| 4   | Wang et al. (2018) | 55 | 29.42 ± 2.34 | 29.11 ± 2.28 | 24.45 ± 1.67 | 24.32 ± 1.41 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po,×5D, Menstruation D5 begins | 4 weeks | ③ |
| 5   | Yu et al. (2018) | 42 | 28.35 ± 3.12 | 28.18 ± 3.88 | not mentioned | not mentioned | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 50 days | ① |
| 6   | Zhang (2018) | 52 | 34.5 ± 3.2 | 32.5 ± 3.6 | 27.6 ± 6 | 26.4 ± 9.6 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×7D, Menstruation D5 begins | 50 days | ① |
| 7   | Zhou et al. (2018) | 60 | not mentioned | not mentioned | not mentioned | not mentioned | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 50 days | ① |
| 8   | Chen (2019) | 40 | 34.5 ± 3.2 | 32.5 ± 3.6 | 27.6 ± 6 | 26.4 ± 9.6 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 50 days | ① |
| 9   | Liu (2019) | 46 | 28.75 ± 2.59 | 29.17 ± 2.66 | 25.68 ± 15 | 26.88 ± 16.56 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 30 days | ②③ |
| 10  | Wang (2019) | 48 | 31.23 ± 3.09 | 31.04 ± 3.21 | 23.04 ± 6.36 | 22.44 ± 5.76 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 3 months | ① |
| 11  | Yang et al. (2019) | 55 | 29.59 ± 8.12 | 29.74 ± 7.19 | 38.76±10.32 | 38.16 ± 9 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 6 months | ②③ |
| 12  | Zhong et al. (2019) | 45 | 28.61 ± 3.11 | 28.56 ± 3.14 | 27.6±8.28 | 26.28 ± 9.36 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 3 months | ① |
| 13  | Fan and Xue (2020) | 46 | 33.96 ± 8.12 | 33.21 ± 7.38 | 27±8.28 | 26.28 ± 9.36 | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 3 months | ②③ |
| 14  | Li (2020) | 50 | 34.56 ± 4.12 | 34.75 ± 3.51 | not mentioned | not mentioned | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 3 months | ②③ |
| 15  | Liu (2020) | 60 | 29.68 ± 2.77 | 30.01 ± 2.21 | 72.6±12.74 | 74.16 ± 13.8 | comparable | ZZ 6 pills bid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 2 months | ②③ |
| 16  | Fan and Xue (2020) | 45 | 29.05 ± 5.36 | 29.11 ± 5.01 | not mentioned | not mentioned | comparable | ZZ 6 pills bid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 2 months | ②③ |
| 17  | Liu (2017) | 48 | 31.7 ± 3.3 | 31.8 ± 3.5 | not mentioned | not mentioned | comparable | KT 2 g tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 3 months | ②③ |
| 18  | Hao and Xia (2018) | 75 | 28.97 ± 4 | 29.02 ± 4.01 | not mentioned | not mentioned | comparable | XJ 3 pills tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | Until preg-nancy or mens-trau-ton | ②③ |
| 19  | Liang et al. (2020) | 44 | 29.25 ± 5.28 | 30.22 ± 6.43 | not mentioned | not mentioned | comparable | XJ 3 pills tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 3 months | ① |
| 20  | Ji et al. (2015) | 30 | 25.4 ± 3.78 | 23.7 ± 4.34 | not mentioned | not mentioned | comparable | YJ 4 pills tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 4 months | ②③ |
| 21  | Zhang et al. (2018) | 47 | 35.61 ± 6.03 | 34.85 ± 6.12 | 22.44±11.4 | 22.08 ± 1.32 | comparable | BL 1 pills tid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D5 begins | 3 months | ③ |
| 22  | Ma (2018) | 40 | 26.2 ± 4 | 25.4 ± 4.2 | 42±13.2 | 44.4 ± 14.4 | comparable | DK 0.5–1 pill bid po + LE | LE 2.5 mg qd po, ×5D, Menstruation D3-5 begins | 3 months | ②③ |
| 23  | Z (2019) | 30 | 29.27 ± 3.59 | 29.17 ± 3.51 | not mentioned | not mentioned | comparable | | | 1 month | ②③ |

(Continued on following page)
letrozole, but there was no statistically significant difference between the other treatment protocols (see Table 4).

**Endometrial Thickness on the Day of Follicular Maturity**

A total of 21 studies (Jian and Bai, 2016; Yang and Huang, 2016; Yang and Zhou, 2016; Chen, 2017; Hao and Xia, 2018; Ma, 2018; Wang et al., 2018; Yu et al., 2018; Zhang, 2018; Zhang et al., 2018; Zhong et al., 2018; Chen, 2019; Wang, 2019; Yang et al., 2019; Zhong et al., 2019; Chu et al., 2020; Fan and Xue, 2020; Li, 2020; Liang et al., 2020; Liu, 2020; Wei et al., 2020) reported the endometrial thickness on the day of follicular maturity after treatment, which was higher in patients using letrozole combined with Kuntai capsules, Fufang Xuanju capsules, or Dingkun Dan than in those using only letrozole. There was no statistically significant difference between the other treatment protocols (see Table 4).

**Sequencing of Network Meta-Analysis Results**

The relative ranking results of the three outcome indicators were different (a lower average ranking is better). Based on the three outcome indicators, the intervention effect of the Fufang Xuanju capsules combined with letrozole was the greatest in terms of increasing the ovulation rate and the endometrial thickness on the day of follicular maturity. In terms of increasing the pregnancy rate, the intervention effect of Dingkun Dan combined with letrozole was the greatest (see Table 5).

**DISCUSSION**

**Discussion on the Components and Pharmacological Effects of Chinese Patent Medicines Involved in This Study**

In this study, except for the Bailing capsule, which is a single plant extract, the other five Chinese patent medicines are all compound preparations. These five types of Chinese patent medicines mainly contain the following traditional Chinese medicines: *rehmanniae radix praeparata* (shu di), *paeoniae radix alba* (bai shao), *asini corii colla* (e jiao), *poria* (fu ling), *angeli anae sinensis radix* (dang gui), *cyperi rhizoma* (xiang fu), *attractylodis macrocephalae rhizoma* (bai shu), *eucommiae cortex* (du zhong), *chuanxiong rhizoma* (chuan xiong), *leonuri herba* (yi mu cao), and *scutellariae radix* (huang qin). See Supplementary Table S1 for detailed composition information.

Modern pharmacological studies have found that *rehmanniae radix praeparata* , *paeoniae radix alba*, and *scutellariae radix* have anti-inflammatory, antioxidant, and immune-regulating effects. *Poria* and *attractylodis macrocephalae rhizoma* can regulate blood glucose and lipid metabolism. *Paeoniae radix alba*, *asini corii colla*, *cyperi rhizoma*, and *leonuri herba* have estrogen-like effects, which can improve ovarian function and regulate the contraction activity of the uterine smooth muscle. *Angeli anae sinensis radix* has an anticoagulant and antithrombotic function and can improve the microcirculation of the reproductive system. *Polyrhachis vicina roger* is the main component of the Fufang Xuanju capsule, and studies have
TABLE 2 | Results of pairwise meta-analysis.

| Interventions | Included studies | OR/MD(95%CI) | P  | Z   | P   | I² (%) | Tau² |
|---------------|-----------------|--------------|----|-----|-----|--------|------|
| **Ovulation rate** | | | | | | | |
| KT + LE vs LE | 5 | 3.52(2.06, 6.04) | 0.0000 | 4.59 | 0.94 | 0 |
| ZZ + LE vs LE | 2 | 8.30(2.76, 25.00) | 0.0002 | 3.76 | 0.96 | 0 |
| XJ + LE vs LE | 1 | 20.24(5.55, 60.32) | 0.004 | 2.85 | | |
| YY + LE vs LE | 1 | 1.80(0.39, 8.32) | 0.45 | 0.75 | | |
| DK + LE vs LE | 3 | 4.06(2.09, 7.91) | 0.0000 | 4.12 | 0.79 | 0 |
| **Pregnancy rate** | | | | | | | |
| KT + LE vs LE | 9 | 2.41(1.80, 3.22) | 0.0000 | 5.94 | 0.81 | 0 |
| ZZ + LE vs LE | 2 | 1.98(1.06, 3.72) | 0.03 | 2.13 | 0.98 | 0 |
| YY + LE vs LE | 1 | 1.41(0.45, 4.45) | 0.56 | 0.58 | | |
| DK + LE vs LE | 3 | 3.76(2.15, 6.60) | 0.0000 | 4.62 | 0.99 | 0 |
| **Endometrial thickness on the follicular maturity day** | | | | | | | |
| KT + LE vs LE | 14 | 2.27(1.70, 2.84) | 0.0000 | 7.84 | 0.0000 | 94 | 0.97 |
| ZZ + LE vs LE | 1 | 2.23(1.56, 2.90) | 0.0000 | 6.49 | | |
| XJ + LE vs LE | 2 | 3.35(0.08, 3.62) | 0.0000 | 24.14 | 0.60 | 0 | 0.00 |
| BL + LE vs LE | 1 | 1.16(0.38, 3.48) | 0.004 | 2.91 | | |
| DK + LE vs LE | 3 | 1.63(0.58, 2.68) | 0.002 | 3.05 | 0.0000 | 91 | 0.77 |

FIGURE 2 | Results of the bias risk assessment of the included studies.

FIGURE 3 | Evidence chart of the ovulation rate/pregnancy rate/endometrial thickness in the network meta-analysis of the different Chinese patent medicines combined with letrozole in the treatment of ovulation disorders.
found that it can coordinate the endocrine system in the body, regulate the synthesis of hormones, and boost immunity. It can also effectively regulate blood sugar and blood lipid levels in the body. The Bailing capsule contains fermented cordyceps powder, which has the effect of regulating immunity and the glucose metabolism of the body.

The composition of Chinese patent medicine is complex, with many drug targets, and the mechanism of the pharmacological action is not completely clear. At present, the main results of the pharmacological research on the six Chinese patent medicines in the treatment of ovulation disorders are as follows:

Bailing capsules can effectively improve glucose metabolism and reduce the degree of insulin resistance in patients, which are important mechanisms in improving ovulation disorders. (Liu et al., 2018)

Fufang Xuanju capsules can stimulate the production of endometrial blood vessels by regulating angiogenic factors, which improves uterine blood circulation, thereby improving the nutritional status of the endometrium. By regulating the nitric oxide levels, it can relieve vascular smooth muscle contractions and improve endometrial blood flow to promote the implantation of the embryo. In addition, the compound Xuanju capsule contains selenium, zinc, and other trace elements, which can effectively regulate the hypothalamic–pituitary–ovarian–uterus axis. (Huang et al., 2016; Zhang et al., 2017)

The Kuntai capsule can improve ovarian function by upregulating the level of superoxide dismutase and regulating the expression of the B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X proteins through the oxidative stress pathway (Geng and Tan, 2017; Zhang et al., 2017) and can also regulate the level of norepinephrine and 5-hydroxytryptamine, which improves ovarian function by regulating the hypothalamic–pituitary–ovarian–uterus axis. (Duan et al., 2014; Zhang et al., 2016)

The Fuke Zaizao capsule can regulate the level of androgens in patients with polycystic ovary syndrome and inhibit the expression of microRNA (miRNA)-383 and miRNA-320 in follicular granulosa cells, which regulates the expression of downstream target genes and hormone synthesis and produces the corresponding biological effect. (Han, 2017)

The Fuke Yangying capsule can effectively improve ovarian blood circulation, promote the development and maturation of dominant follicles, promote ovulation, improve luteal function, and improve endometrial receptivity to increase pregnancy and embryo survival rates. (Xie et al., 2012)

Dingkun Dan has an estrogen-like effect, (Li et al., 2016) can dilute cervical mucus during the period surrounding ovulation, is conducive to sperm penetration, can improve ovarian function, can promote follicle development, and can increase the ovulation rate. (Zhai, 2019) In addition, it can promote endometrial growth, improve endometrial receptivity, and increase the pregnancy rate in patients struggling with infertility. (Huang, 2018)

Mechanism of Ovulation Induction by Letrozole

Ovulation disorders are the main cause of infertility or difficulty achieving pregnancy in women of childbearing age who require fertility treatment, which seriously affects women’s physical and mental health and family harmony.
### TABLE 4 | Results of network meta-analysis of different Chinese patent medicines combined with letrozole in the treatment of ovulation disorders.

| Interventions | Ovulation rate | Pregnancy Rate | Endometrial thickness on the follicular maturity day |
|---------------|----------------|----------------|-----------------------------------------------------|
|               | KT + LE        | ZZ + LE        | BL + LE                                             |
| 3.185 (0.7724, 9.7730) | 19.3000 (0.3382, 93.360) | 0.0560 (0.0014, 0.2164) | 3.3660 (1.8270, 4.9150) |
| 43.050 (1.1800, 212.10) | 0.0167 (0.0019, 0.8321) | 1.1620 (−1.1200, 3.437) | 0.0420 (0.3441, 2.9080) |
| 0.8054 (0.0990, 3.1900) | 0.1620 (0.0049, 0.9483) | 0.0000 (0.0000, 0.0000) | 0.0015 (0.0000, 0.0000) |
| 1.1670 (0.4391, 2.5550) | 2.9500 (0.3124, 11.190) | 2.197 (0.0101, 1.4970) | 2.2720 (1.661, 2.9160) |
| 0.2858 (0.1580, 0.4700) | 0.7232 (0.0928, 2.5160) | 0.0640 (0.0014, 0.2164) | (−0.0146, 4.4850) |

### TABLE 5 | Sequencing results of network meta-analysis of different Chinese patent medicines combined with letrozole in the treatment of ovulation disorders.

| Interventions | Ovulation rate | Pregnancy rate | Endometrial thickness on the follicular maturity day |
|---------------|----------------|----------------|-----------------------------------------------------|
|               | WinBugs results | Rank | WinBugs results | Rank | WinBugs results | Rank |
| KT + LE        | 0.0015          | 5    | 0.0560          | 3    | 0.0420          | 3    |
| ZZ + LE        | 0.1596          | 2    | 0.0493          | 4    | 0.1726          | 2    |
| YY + LE        | 0.0089          | 3    | 0.0622          | 2    | 0.7344          | 1    |
| BL + LE        | -               | -    | -               | -    | -               | -    |
| DK + LE        | 0.0040          | 4    | 0.8325          | 1    | 0.0167          | 5    |
| LE             | 0.0000          | 6    | 0.0000          | 5    | 0.0000          | 6    |
Ovulation induction is the main treatment for ovulation disorders, and letrozole, a third-generation aromatase inhibitor, is currently commonly used to promote ovulation. When compared with clomiphene, a first-line ovulatory drug, letrozole has been shown to reduce the risk of ovarian hyperstimulation syndrome, increase the endometrial thickness, and improve the cervical mucus score. (Yu Q. et al., 2019; Behnoud et al., 2019)

The Possible Pharmacological Effects of Chinese Patent Medicine and Letrozole on Ovulation Induction

Although letrozole has many advantages over clomiphene for ovulation induction, numerous clinical studies have found that due to the short half-life of the drug, the effect of letrozole decreases continuously as estrogen levels drop in the later stage of follicular development, resulting in the possibility that the dominant follicles may not be released. Various studies have shown that the success rate of letrozole for ovulation induction is about 70–84%, but the pregnancy rate is only 20–27%. (Yu Z. Z. et al., 2019)

According to the pharmacological effects of the abovementioned Chinese patent medicines, the author believes that Chinese patent medicine can achieve complementary effects with letrozole, such as regulating glucose metabolism, alleviating insulin resistance, improving endometrial blood circulation, promoting endometrial growth, improving endometrial receptivity, regulating hormone levels and the reproductive axis, and improving the conception rate, thus improving the efficacy of letrozole in treating ovulation disorders.

The Feasibility of Using Chinese Patent Medicine in Combination With Letrozole in the Treatment of Ovulation Disorders

In traditional Chinese medicine theory, the kidney dominates reproduction: “... kidney dominates Chong and Ren meridian, Chong meridian is the repository of blood, Ren meridian connects with the uterus and pregnancy.” Therefore, there is a close relationship between fertility and both kidney deficiency and the disharmony of the qi and blood of zang-fu. Tonifying the kidney and filling essence and harmonizing the qi and blood are the main methods to treat infertility. Doctors in Western hospitals and general hospitals in China are more inclined to use Chinese patent medicine to treat ovulation disorders when they are combined with ovulation promoting medicines. The Chinese patent medicines in this study, which tonify the kidney and harmonize the qi and blood, are recognized by the majority of front-line doctors in clinical practice.

This study evaluated the efficacy of six Chinese patent medicines combined with letrozole in the treatment of ovulation disorders. The results showed that the combination of Fufang Xuanju capsules and letrozole was more effective than the other intervention measures in improving the ovulation rate and endometrial thickness on the day of follicular maturity, and the combination of Dingkun Dan and letrozole was better than other the intervention measures in improving the pregnancy rate.

The Innovations and Limitations of This Study

Chinese patent medicines are widely used on the clinical front line, especially by gynecologists and reproductive doctors in general hospitals. In this study, the maximum number of citations for a single Chinese patent medicine pharmacological study was 115 times, and the maximum number of citations for a single article in the literatures included in the NMA was 38 times (See Supplementary Table S2 for specific citation times). It can be seen that Chinese patent medicine has always been a hot topic in Medical research in China. However, in the past, there has been little comparison of efficacy and professional guidelines for various Chinese patent medicines.

This study is part of the project of Guidelines on clinical application of Chinese patent medicines Standardized Program. This project was set up by the State Administration of Traditional Chinese Medicine, and dozens of general hospitals in first-tier cities across the country participated in it. By looking for evidence-based medicine evidence and combining expert clinical drug use experience, expert consensus was finally reached, and guidelines were formed and issued to guide clinical front-line doctors to use Chinese patent medicines. This is of great significance for reducing clinical risk and improving clinical efficacy.

In previous studies, there was a lack of comparison of efficacy of many proprietary Chinese medicines. In this paper, the advantages and disadvantages of six proprietary Chinese medicines in the treatment of ovulation disorders were analyzed, providing a reference for clinical front-line doctors, and laying a foundation for the development of relevant guidelines in the next step.

Of course, there are still limitations: 1) The quality of the included research is low. Some of the literature did not clarify the random method, and all of the literature lacked an appropriate blinding method, so the results of this NMA are likely to be biased to some extent. The potential risks associated with this bias may affect the authenticity and reliability of the results and lead to reduced test performance. 2) The sample size of the included literature is small, and the statistical efficacy may be insufficient. 3) The quality of results from the NMA was not graded in this study. Based on the defects of the existing research, the decision makers should consider the influence of the above factors and consider carefully when applying the research conclusions.

Therefore, there is a need for relevant studies in the future to further optimize the design scheme of clinical trials. It is expected that future studies can further guide the rational use of drugs in the clinical setting.

CONCLUSION

Through network meta-analysis, we demonstrated that Letrozole combined with Chinese patent medicine was more effective than letrozole alone in the treatment of ovulation disorders. Fufang Xuanju capsules was good at improving the ovulation rate and increasing the endometrial thickness. Dingkun Dan was good at
improving the pregnancy rate. These founding can provide an important reference for clinicians in specific medication.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS
J-YZ, JL and X-JC conceived the idea and conceptualised the study. J-YZ and X-JC collected the data. J-YZ and X-YW drafted the article, then J-YZ and X-YW reviewed the article. All authors read and approved the final draft.

FUNDING
Guidelines on clinical application of Chinese patent medicines Standardized Program (Project No.: SATCM-2015-BZ402-002). National Natural Science Foundation of China (No.82004411). National Key R&D Program (No.2018YFC1704100). State Administration of Traditional Chinese Medicine (No.(2016)42). Science and Technology Planning Project of Guangdong Province (No.2017B030314166). Guangdong Provincial Natural Science Foundation (No.2018A03010508). Guangdong Hospital of traditional Chinese Medicine (No.(2013)233).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.722122/full#supplementary-material

REFERENCES
Ades, A. E., Sculpher, M., Sutton, A., Abrams, K., Cooper, N., Welton, N., et al. (2006). Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis. *PharmacoEconomics* 24 (1), 1–19. doi:10.2165/00019053-200624010-00001
Behnoud, N., Rezaei, R., Esform, E., and Farzaneh, F. (2019). The Relationship between Endometrial Thickness and Endometrial Pattern with Pregnancy Rate Based on Positive Serum Beta-Human Chorionic Gonadotropin. *Int. J. Women’s Health Reprod. Sci.* 7, 400–403. doi:10.15296/iwjhrs.2019.65
Chen, F. (2019). Analysis of the Effect of Kuntai Capsule Combined with Letrozole in Treating Infertility Due to Polycystic Ovary Syndrome. *China Med. Eng.* 27, 65–67. doi:10.19338/j.issn.1672-2019.2019.04.017
Chen, G. F. (2017). Effect of Kuntai Capsule Combined with Letrozole in the Treatment of Polycystic Ovary Syndrome in Ovulation Induction. *J. Med. Theor. Prac.* 30, 2590–2591. doi:10.19381/jissn.1001-7585.2017.17.046
Chu, J. J., Wang, X. L., and Wang, R. X. (2020). Clinical Observation of Dingkun Dan Combined with Letrozole in the Treatment of Infertility Due to Kidney Deficiency Syndrome Polycystic Ovary Syndrome. *J. Anhui Univ. Chin. Med.* 39, 27–31. doi:10.3969/j.issn.2095-7246.2020.03.008
Dias, S., Sutton, A. J., Ades, A. E., and Welton, N. J. (2013). Evidence Synthesis for Decision Making 2: a Generalized Linear Modeling Framework for Pairwise and Network Meta-Analysis of Randomized Controlled Trials. *Med. Decis. Making* 33 (5), 607–617. doi:10.1177/0272989X12458724
Duan, Y. K., Li, L., and Li, J. D. (2014). Effects of Kuntai Capsule on Hormone Level and Perimenopausal Syndrome in the Menopausal Rats[J]. *Chin. Hosp. Pharm.* 34 (06), 432–435. doi:10.13286/j.cnki.chinpharmacy.2014.06.03
Fan, X. L., and Xue, H. X. (2020). Application Effect of Letrozole Combined with Kuntai Capsule in Patients with Polycystic Ovarian Syndrome. *Clin. Med. Res. Pract.* 5, 121–123. doi:10.19347/j.cnki.2096-1413.202009053
Geng, L. H., and Tan, Y. (2017). Effect of Kuntai Capsule on Expressions of Bel-2 and Bax Protein in Rats Ovaries with Decreasing Ovarian Reserve[J]. *Chin. J. Exp. Traditional Med. Formulae* 23 (08), 138–143. doi:10.15422/j.cnki.xjyk.2017080138
Han, Y. B. (2017). Study on the Effect of Fuke Zaizao Capsule on miRNA-383 and miRNA-320 of Polycystic Ovarian Syndrome[J]. *Mod. Med. J.* 45 (01), 100–102. doi:10.3969/j.issn.1671-7562.2017.01.025
Hao, L. N., and Xia, T. E. (2018). Clinical Efficacy of Fufang Xuanju Capsules Combined with Letrozole in the Treatment of Polycystic Ovary Syndrome Infertility. *Clin. Med. Res. Pract.* 3, 138–139. doi:10.19347/j.cnki.2096-1413.2018032062
Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring Inconsistency in Meta-Analyses. *BMJ* 327 (7414), 557–560. doi:10.1136/bmj.327.7414.557
Huang, R. L. (2018). Clinical Observation on Dingkun Dan in the Treat Men of Ovulatory Dysfunctional Infertility[J]. *Chin. Med. Med. Dist. Educ. China* 16 (12), 120–122. doi:10.3969/j.issn.1672-2779.2018.12.053
Huang, Y. F., Lu, X. Y., and Liang, J. M. (2016). Clinical Efficacy of Compound Xuanju Capsule in the Adjutant Treatment of Ovulation Disorder Infertility and its Effect on the Level of Sex Hormones[J]. *Tianjin Pharm.* 28 (05), 38–40.
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., et al. (2015). The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations. *Ann. Intern. Med.* 162 (11), 777–784. doi:10.7326/M14-2385
Ji, N., Liu, Y. Q., and Liu, R. X. (2015). Etc. Clinical Observation of Fuke Yangying Capsule Combined with Letrozole in the Treatment of Infertility Due to Polycystic Ovary Syndrome. *J. Shaoxi Coll. Traditional Chin. Med. 38, 58–60. doi:10.13424/j.cnki.jsctcm.2015.04.021
Jian, Q. Q., and Bai, J. H. (2016). Clinical Analysis of Gynecological Reworking Capsules Combined with Lelrozol in Treatment of Anovulatory Infertility. *Cancer Pract.* 28, 96–99. doi:10.3969/j.issn.2095-140X.2016.02.025
Li, Q. J., Lu, H., and Liu, Y. (2016). Infrared thermal Imaging Assesses the Effectiveness of Kuntai Capsule in Patients with Polycystic Ovary Syndrome. *Clin. Med.* 38 (12), 2560–2565. doi:10.3969/j.issn.1001-1528.2016.12.007
Li, X. L. (2020). Kuntai Capsule Combined with Letrozole OI in Patients of Infertility with Polycystic Ovary Syndrome. *Chin. J. Rational Drug Use* 17, 58–62. doi:10.3969/j.cnki.jszd.2016.01528.2016.12.007
Li, X. L. (2020). Kuntai Capsule Combined with Letrozole OI in Patients of Infertility with Polycystic Ovary Syndrome. *Chin. J. Rational Patent Med.* 38 (12), 2560–2565. doi:10.3969/j.issn.1001-1528.2016.12.007
Li, X. L. (2020). Kuntai Capsule Combined with Letrozole OI in Patients of Infertility with Polycystic Ovary Syndrome. *Chin. J. Rational Drug Use* 17, 58–62. doi:10.3969/j.cnki.jszd.2016.01528.2016.12.007
Li, Y. Q., Huang, B., and Wei, S. L. (2020). Etc. Clinical Observation of Fufang Xuanju Capsules Combined with Letrozole in the Treatment of Infertility Due to Polycystic Ovary Syndrome Infertility. *Chinese Patent Med.* 38, 99. doi:10.3969/j.issn.2095-8803.2020.01.070
Liu, L. J. (2019). Clinical Efficacy of Kuntai Capsule Combined with Letrozole in Treatment of Polycystic Ovary Syndrome. *North. Pharm.* 16, 5–6.
Liu, X., Pi, D., and Liu, C. M. (2018). Effect of Bailing Capsule Combined with Ethinylestradiol and Cyproterone Acetate and Metformin on Lipid Metabolism and Insulin Resistance in Patients with Polycystic Ovary Syndrome[1]. J. Hainan Medical Univ. 24 (02), 224–227. doi:10.13210/j.cnki.hjmu.20171226.003

Liu, X. Q. (2020). Effect of Kuntai Capsule on Endocrine Level and Pregnancy in Patients with Ovary Disorder of Spleen and Kidney Deficiency. Clin. J. Traditional Chin. Med. 32, 497–499. doi:10.16448/j.jctcm.2020.0328

Liu, Z. (2017). Curative Effect Study on the Gynecological Reconstruction Capsule Combined with Letrozole on Ovulation Induction in PCOS Patients. Heilongjiang Med. J. 31, 1035–1037. doi:10.14035/j.cnki.hljyy.2018.05.044

Vitek, W., and Hoeger, K. (2019). Letrozole versus Clomiphene In polycystic Ovary Syndrome-More Than One Way to Crack an Egg. Fertil. Steril 111, 469–470. doi:10.1016/j.jfertstert.2018.12.020

Yang, S. P., Liu, Q., and Wang, M. L. (2019). Effect of Kuntai Capsules Combined with Letrozole on Ovulation Induction in Patients with Polycystic Ovary Syndrome. J. Reprod. Med. 19, 31–33. doi:10.13638/j.issn.1671-4040.2019.07.015

Yang, S. P., Liu, Q., and Wang, M. L. (2019). Effect of Kuntai Capsules Combined with Letrozole in the Treatment of Polycystic Ovary Syndrome. Clin. Appl. integrated Chin. West. Med. 19, 31–33. doi:10.13638/j.issn.1671-4040.2019.07.015

Zhang, J., Fang, L., Shi, L., Lai, Z., Lu, Z., Xiong, J., et al. (2017). Protective Effects and Mechanisms Investigation of Kuntai Capsule on the Ovarian Function of a Novel Model with Accelerated Aging Ovaries. J. Ethnopharmacol 195, 173–181. doi:10.1016/j.eph.2016.11.014

Zhang, Q. X., Zhang, D. Q., and Huang, C. L. (2016). Effect of Kuntai Capsule on Neurotransmitter in Old Rats[J]. J. Tianjin Univ. Traditional Chin. Med. 35 (03), 173–175. doi:10.11656/j.issn.1673-9043.2016.03.07

Zhang, S. W., and Yu, Y. X. (2017). Efficacy of Xuanju Capsule with Progynova in Treatment of Thin Endometrium[J]. J. Reprod. Med. 26 (05), 457–463. doi:10.1369/j.issn.1004-3845.2017.05.014

Zhang, Y. C., Li, L. L., and Shi, H. X. (2018). Etc. Effects of Bailing Capsule Combined with Letrozole on Endometrial Thickness and Serum Levels IGF-1 and Visfatin in Patients with Polycystic Ovary Syndrome. J. Guangxi Med. Univ. 35, 1233–1236. doi:10.13638/j.issn.1671-4040.2018.04.020

Zhang, Y. (2018). Effects of Kuntai Capsule Combined with Letrozole on Ovulation Induction and Uterine Blood Flow of Ovulation Failure Infertility in Infertile PCOS Patients. Chin. Appl. integrated Chin. West. Med. 18, 44–46. doi:10.13638/j.issn.1998-2927.2020.06.044

Zhang, Y. (2018). Effects of Kuntai Capsule Combined with Letrozole on Ovulation Induction in Infertile Patients with Polycystic Ovary Syndrome. Matern. Child Health Care China 35, 1105–1107. doi:10.1016/j.jfertstert.2018.12.020

Zhang, Y. (2018). Effects of Kuntai Capsule Combined with Letrozole on Ovulation Induction in Patients with Polycystic Ovary Syndrome. J. Reprod. Med. 19, 31–33. doi:10.13638/j.issn.1671-4040.2019.07.015

Zhang, Y. (2018). Effects of Kuntai Capsule Combined with Letrozole on Ovulation Induction in Infertile PCOS Patients. Clin. Appl. integrated Chin. West. Med. 18, 44–46. doi:10.13638/j.issn.1998-2927.2020.06.044

Zhang, Y. (2018). Effects of Kuntai Capsule Combined with Letrozole in Treatment of Infertile PCOS Patients. Clin. Appl. integrated Chin. West. Med. 18, 44–46. doi:10.13638/j.issn.1998-2927.2020.06.044

Zhang, Z. J., Fang, L., Shi, L., Lai, Z., Lu, Z., Xiong, J., et al. (2017). Protective Effects and Mechanisms Investigation of Kuntai Capsule on the Ovarian Function of a Novel Model with Accelerated Aging Ovaries. J. Ethnopharmacol 195, 173–181. doi:10.1016/j.eph.2016.11.014

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.